Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia

澳大利亚新南威尔士州一项基于人群的队列研究:原发性黑色素瘤诊断中初始活检技术的差异

阅读:1

Abstract

BACKGROUND: Factors associated with nonadherence to guideline-recommended complete excision of suspicious cutaneous lesions are unclear. OBJECTIVE: The purpose of this study was to analyze patient, melanoma, and clinician factors associated with initial diagnostic biopsy type and determine whether unwarranted variation from guidelines occurred. METHODS: This population-based, cohort study involved the analysis of data from questionnaires completed by clinicians who managed patients with newly diagnosed, histopathologically confirmed primary invasive cutaneous melanomas reported to the New South Wales Cancer Registry between 2006 and 2007. RESULTS: Of the 2267 biopsies, complete excision was attempted in 69.1% of cases but histologically incomplete in 14.0%. Multivariable regression analyses showed that complete excision was more likely than incision biopsy in patients <70 years (P = .016), shave biopsy in patients <80 years (P = .034), shave biopsy in melanomas of Breslow thickness 0.8-1.0 mm or 2.1-4.0 mm (P = .039) than either punch (P < .001) or shave biopsy (P < .003) in melanomas on trunk or limbs, and punch biopsy when treated by a surgeon (P < .001). Complete excision was less likely than punch biopsies in women (P < .003), with lentigo maligna melanoma or unknown histopathology (P = .004); shave biopsy in patients with lentigo maligna melanoma, or other melanoma subtype (P = .003); punch, shave, or incision biopsy when treated by a dermatologist (P < .001). LIMITATIONS: Generalizability of these findings may be limited to the time of data collection. CONCLUSIONS: Guideline adherence for biopsy type undertaken for clinically suspected melanoma appeared to be suboptimal.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。